Presentation by Andrew Jenner, Director of Innovation, IP and Trade at the IFPMA. Geneva Pharma Forum on Biopharmaceutical Innovation and Legal Certainty (WIPO, 17 April 2012).
Read moreCode extended to cover all interactions with healthcare professionals, medical institutions, and patient organizations Code provides effective framework for ethical business practices International patient organization welcomes new rules IFPMA encourages equally high standards across healthcare sector 1 March 2012, Geneva – Today the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) announced an expansion of...
Read moreDonations focused on meeting new WHO targets for maximum impact against NTDs Builds on industry’s long‐standing record of innovating treatments for neglected tropical diseases 30 January 2012, Geneva – Today the research-based pharmaceutical industry announced donations of 14 billion treatments this decade to support the elimination or control of nine key neglected tropical diseases (NTDs). Averaging 1.4 billion treatments annually, the donations build upon companies’ existing medicines donation programmes which already reach millions of people around...
Read moreMarc Wortmann, Executive Director, Alzheimer’s Disease International, sits down with Ali Karami-Ruiz, IFPMA, to discuss latest trends on mental & neurological disorders.
Read moreDr. Shekhar Saxena, Director, Department of Mental Health and Substance Abuse, World Health Organization, sits down with Mario Ottiglio, IFPMA, to discuss latest trends on mental & neurological disorders.
Read moreNorman Sartorius, President of the Association for the Improvement of Mental Health Programmes, sits down with Ali Karami-Ruiz, IFPMA, to discuss social challenges to fight mental & neurological disorders.
Read morePeter Hongaard, Senior VP of External Scientific Affairs for Lundbeck, sits down with Mario Ottiglio, IFPMA, to discuss the research challenges in the mental & neurological disorders arena.
Read more